维普期刊资源整合服务平台（V6.5）

55篇 您的检索式：作者名="Soverini"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013显示文摘	Michele Baccarani Michael W. Deininger Gianantonio Rosti Andreas Hochhaus Simona Soverini Jane F. Apperley Francisco Cervantes Richard E. Clark Jorge E. Cortes Fran?ois Guilhot Henrik Hjorth-Hansen Timothy P. Hughes Hagop M. Kantarjian Dong-Wook Kim Richa	2013	Blood2013，，6：	3
2	Targeted therapy and the T315I mutation in Philadelphia-positive leukemias显示文摘	Soverini S Iacobucci I Baccarani M	2007	Haematologic2007，92，4：	1
3	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors:recommendations from an expert panel on behalf of European Leukemia Net显示文摘	Soverini S Hochhaus A Nicolini FE	2011	{H}Blood2011，，05：	1
4	Binding mode of the tyrosine kinase inhibitor bosutinib (SKI-606) to Abl kinase 显示文摘	SOVERINI S TASCO G GRAFONE T	2007	J Clin Oncol2007，25，18：	1
5	Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Phila- delphia-positive Patients The GIMEMA Working Party on Chronic My- eloid Leukemia显示文摘	Soverini S Colarossi S Gnani A	2006	Clin Cancer Res2006，12，24：	1
6	Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias 显示文摘	Nicolini FE Basak GW Soverini S	2011	Blood2011，118，：	1
7	ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival : a study by the GIMEMA Working Party on Chronic Myeloid Leukemia显示文摘	Soverini S Martinelll G Rosti G	2005	J Clin Oncol2005，23，18：	1
8	The frish scheme in dynamic system identification 显示文摘	BEGHELLI S GUIDORZI R P SOVERINI V	1990	Automatica1990，326，8：	1
9	Allogeneic stem cell transplantation for patients harboring T315I BCRABL mutated leukemias显示文摘	Nicolini FE Basak GW Soverini S	2011	Blood2011，118，20：	1
10	Intermittent targeting as a tool to minimize toxicity of tyrosine kinase in- hibitor therapy显示文摘	Martinelli G Soverini S Iacobucci I	2008	J Clin Oncol2008，26，：	1
11	Long-term mutation follow-up of philadelphia-chromosome positive leukemia patients treated with second-generation tyrosine kinase inhibitors after imatinib failure shows that newly acquired ber-abl kinase domain mutations leading to relapse are mainly detected during the first year 显示文摘	SOVERINI S	2008	Blood ( ASH Annual Meeting Abstracts)2008，112，：	1
12	Molecliar monitoringand mutations in chronic myeloid leukemia : how to get the mostout of your tyrosine kinase inhibitor 显示文摘	Baccarani M Soverini S De Benedittis C	2014	Am !50c Clin OncolEduc Book2014，34，：	1
13	European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013显示文摘	Baccarani M Deininger M W Rosti G Hochhaus A Soverini S Apperley J F	2013	Blood2013，122，：	1
14	Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis显示文摘	Luca Valenti Anna Ludovica Fracanzani Raffaela Rametta Mirella Fraquelli Giulia Soverini Serena Pelusi Paola Dongiovanni Dario Conte Silvia Fargion	2012	Journal of Hepatology2012，，6：	1
15	Second-line treatment with dasatinib in patients resistant to imatinib can select novel imhibitor-specific BCR-AbL mutants in ph《'+》 ALL显示文摘	Martinelli G Colarossel S	2007	Lancet Oncol2007，8，2：	1
16	Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia显示文摘	Soverini S Colarossi S Gnani A	2006	Clin Cancer Res2006，12，24：	1
17	Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias显示文摘	Nicolini FE Basak GW Soverini S		Blood0，，：	1
18	Identification of dynamic errors-in-variables model:Approaches based on two-dimensional ARMA modeling of the data显示文摘	S(o)derstr(o)m T Mahata K Soverini U		0，，：	1
19	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet 显示文摘	Soverini S Hochhaus A Nicolini FE	2011	Blood2011，118，5：	1
20	Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome- positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement 显示文摘	Soverini S De Benedittis C Papayannidis C	2014	Cancer2014，120，7：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示